Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

10 Feb 2026 - 13 Feb 2026
17 Apr 2026 - 21 Apr 2026

Sensitive Urine Assay Detects Prostate Cancer

By LabMedica International staff writers
Posted on 29 Aug 2011
An innovative prostate screening test has been developed that may be more sensitive in detecting prostate cancer than traditional screening methods. More...


The test provides an original way to look at prostate cancer diagnosis utilizing a novel biological assay, which differentiates prostate-specific antigen's (PSA) molecular structures arising from cancer versus noncancerous glands.

Scientists at Case Western Reserve University School of Medicine collaborating with other institutions, studied a urine-based test that works differently than most prostate screening methods. They used a novel assay to separate PSA protein structures as being linked to either a “cancer” or “noncancer” pathologic diagnosis based on ultrasound-guided biopsy. Instead of attempting to find a single genetic biomarker, which predicts the presence of cancer, the Prostate-specific Antigen/Solvent Interaction Analysis (PSA/SIA) assay is based on the assumption that there may be myriad different ultrastructural changes in the PSA protein, which define the cancer phenotype.

The PSA/SIA assay determined the relative partitioning of heterogeneous PSA isoform populations in urine between two aqueous phases. The initial study, collected at three clinical sites, followed 222 men, and found that the new screening method had 100% sensitivity with no false negative results and 80.3% specificity showing low false positive results. The accuracy of traditional serum PSA is limited by both relatively high false positive and false negative rates. Current diagnostic strategies that use total PSA to determine the need for biopsy demonstrate false positive rates of approximately 55% to 75%.

The PSA/SIA assay, a product of AnalizaDx (Cleveland, OH, USA) provides ratiometric information independently of PSA concentration. In the preliminary study, analysis of the overall structurally heterogeneous PSA isoform population using the SIA assay showed promising results to be further evaluated in future studies. Arnon Chait, PhD, CEO of AnalizaDx, said, "This new assay is a complete departure from how the scientific community has looked at biomarkers for cancer. Instead of just measuring levels of proteins, we are exploring changes in structure which are associated with cancer.” The study was published online on July 22, 2011, in the journal Urology.

Related Links:
Case Western Reserve University School of Medicine
AnalizaDx




New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
POC Helicobacter Pylori Test Kit
Hepy Urease Test
ESR Analyzer
TEST1 2.0
Automatic CLIA Analyzer
Shine i9000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.